DDInter1596 DDInter1840
A glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis. Riluzole is marketed as Rilutek by Sanofi.
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Riluzole {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Alanine aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Riluzole {u} (Compound) downregulates {v} (Gene) CDKN1B
CDKN1B {u} (Gene) interacts with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Riluzole {u} (Compound) upregulates {v} (Gene) PTK2B
PTK2B {u} (Gene) is regulated by {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Riluzole {u} (Compound) upregulates {v} (Gene) KIT
KIT {u} (Gene) interacts with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Riluzole {u} (Compound) upregulates {v} (Gene) PTK2B
PTK2B {u} (Gene) covaries with {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Trabectedin
Riluzole {u} (Compound) upregulates {v} (Gene) SYK
SYK {u} (Gene) interacts with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Riluzole {u} (Compound) downregulates {v} (Gene) TERF2IP
TERF2IP {u} (Gene) is regulated by {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Riluzole {u} (Compound) downregulates {v} (Gene) TXLNA
TXLNA {u} (Gene) regulates {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Riluzole {u} (Compound) downregulates {v} (Gene) STUB1
STUB1 {u} (Gene) interacts with {v} (Gene) and {u} (Gene) is regulated by {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Riluzole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Caffeine
Caffeine {u} (Compound) binds {v} (Gene) CYP2E1
CYP2E1 {u} (Gene) is bound by {v} (Compound) Trabectedin
Riluzole (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Trabectedin (Compound)
Riluzole (Compound) downregulates CDKN1B (Gene) and CDKN1B (Gene) interacts with SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Riluzole (Compound) upregulates PTK2B (Gene) and PTK2B (Gene) is regulated by SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Riluzole (Compound) upregulates KIT (Gene) and KIT (Gene) interacts with SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Riluzole (Compound) upregulates PTK2B (Gene) and PTK2B (Gene) covaries with CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Trabectedin (Compound)
Riluzole (Compound) upregulates SYK (Gene) and SYK (Gene) interacts with SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Riluzole (Compound) downregulates TERF2IP (Gene) and TERF2IP (Gene) is regulated by SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Riluzole (Compound) downregulates TXLNA (Gene) and TXLNA (Gene) regulates SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Riluzole (Compound) downregulates STUB1 (Gene) and STUB1 (Gene) interacts with SRC (Gene) and STUB1 (Gene) is regulated by SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Riluzole may cause a minor interaction that can limit clinical effects when taken with Caffeine and Caffeine (Compound) binds CYP2E1 (Gene) and CYP2E1 (Gene) is bound by Trabectedin (Compound)